blu-945
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jun 29, 2021 (NCT04862780)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
- Adenocarcinoma · Phase 1/Phase 2
- Antineoplastic Agents · Phase 1/Phase 2
- Bronchial Neoplasms · Phase 1/Phase 2
- Carcinoma · Phase 1/Phase 2
- Carcinoma, Bronchogenic · Phase 1/Phase 2
- Carcinoma, Non-Small-Cell Lung · Phase 1/Phase 2
- Epidermal Growth Factor · Phase 1/Phase 2
- Lung Diseases · Phase 1/Phase 2
- Lung Neoplasms · Phase 1/Phase 2
- Mutation · Phase 1/Phase 2
- Neoplasms · Phase 1/Phase 2
- Neoplasms by Histologic Type · Phase 1/Phase 2
- Neoplasms by Site · Phase 1/Phase 2
- Neoplasms, Nerve Tissue · Phase 1/Phase 2
- Protein Kinase Inhibitors · Phase 1/Phase 2
- Respiratory Tract Diseases · Phase 1/Phase 2
- Respiratory Tract Neoplasms · Phase 1/Phase 2
- Thoracic Neoplasms · Phase 1/Phase 2
Mechanism of action
EGFR inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CO[C@@H]1CCN(c2nccc(Nc3cc4c(C(C)C)ccc(N5C[C@H](CS(C)(=O)=O)[C@H]5C)c4cn3)n2)C[C@@H]1F- Mol. weight
- 556.71 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5095169 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04862780 | Phase 1/Phase 2 (Phase 2) | Jun 29, 2021 | Blueprint Medicines Corporation |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Blueprint Medicines Corporation | For profit | 1 | 1 | 1 | 2021 |
1 organizations
Page 1 / 1